Navigation Links
Four Community Hospitals Join DNA Direct's Genomic Medicine Network
Date:1/31/2011

SAN FRANCISCO, Jan. 31, 2011 /PRNewswire/ -- DNA Direct, a wholly owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS) and a leading provider of guidance and decision support for genomic medicine, announced today that Aspirus Wausau Hospital of Wausau, Wisconsin, Atlantic Health of Morristown, New Jersey, Crittenton Hospital Medical Center of Rochester, Michigan and Swedish Covenant Hospital of Chicago, Illinois, have joined the Genomic Medicine Network to provide personalized medicine services to their patients.

(Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO)

"We are very excited to have these innovative hospitals join the Genomic Medicine Network," said Ryan Phelan, Founder & President of DNA Direct. "Community hospitals are facing a challenging environment today and integrating personalized medicine into clinical care is a great way for hospitals to differentiate their services, educate medical staff and improve patient outcomes."

Launched in 2009, the Genomic Medicine Network (GMN) provides hospitals with both a patient and physician web-based personalized medicine portal. The patient portal provides educational content, decision support to help determine test appropriateness and access to genetic experts.

The physician portal assists physicians and medical staff as they make informed decisions that improve patient outcomes and includes web-based decision support, continuing education and training and access to genetic counselors that are available for consult.

With more than 2,000 diseases for which molecular diagnostic and genetic tests are available today, physicians need support determining which tests are clinically appropriate and clear guidance for diagnosis and treatment decisions. DNA Direct's resources help physicians identify risks and better understand when genetic or personalized medicine tests may be appropriate.

Findings from a national benchmark survey, conducted in 2009 by Medco and the American Medical Association, showed that while the vast majority of physicians recognize the contribution of genetic tests for improving medication response by guiding the prescribing and dosing of many widely used medications, most doctors don't feel they know enough about these tests to put them into practice. In 2010, Medco released new data from a study that also showed that when both physicians and patients are informed about choices regarding testing and the process is made convenient, the adoption of genetic tests is substantially increased.

Physicians and their patients can use genetic information to not only better understand health risks, but to also choose therapies that will work best based on their genetic profile, and pursue prevention strategies for common diseases.

"We at Atlantic Health are excited to add Personalized Medicine services working with DNA Direct and its Genomic Medicine Network. We believe that genomic medicine is becoming an important part of day-to-day medical practice and a key piece of the puzzle as we all seek to better stratify risk factors and improve care for our patients," said Dr. Arnold Pallay, Director of Primary Care Genomics at Atlantic Health. "Providing a community portal, decision support tools and physician education goes a long way towards meeting the needs of patients and physicians alike. We look forward to offering our community these services and also collaborating with the other innovative hospitals in the network on research protocols, clinical consulting and educational experiences."

The GMN brings physicians together across the country as peers to share best practices, clinical experiences and general knowledge across all specialties. The network is comprised of forward-thinking hospitals focused on innovation and is a valuable collaborative environment. The network will also work together in personalized medicine research studies, clinical trials, and personalized medicine programs based on the unique demographics of each hospital.

About DNA Direct

DNA Direct, a wholly owned subsidiary of Medco Health Solutions, delivers guidance and decision support for genomic medicine to patients, providers and payers. The company's comprehensive clinical programs are unique to genomic medicine, and combine proprietary technology with genetic expertise, including a national call center of genetic experts, web-based applications, and educational resources and training. The company is based in San Francisco. For more information, visit www.dnadirect.com.


'/>"/>
SOURCE DNA Direct
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony
2. Bunker Hill Community College Wins Major Endorsement for Biotechnology Courses
3. UBM Medica Acquires Leading Online Community OBGYN.net
4. BioSpace and BioMed Central Create Global Career Community
5. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
6. Clean Power Development, LLC Urges Sustainable, Community-Centric Approach to Biomass Energy
7. All-New Sermo Brings Major Enhancements to Nations Largest Online Physician Community
8. Alexandria Real Estate Equities, Inc. Receives Final Approval From City of Cambridge to Develop Its East Cambridge State-of-the-Art Life Science Community
9. Netsmart Announces My Avatar at National Council for Community Behavioral Healthcare Annual Conference
10. BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge
11. Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... 23, 2016 ReportsnReports.com adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):